Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hoth Therapeutics

1.13
-0.0400-3.42%
Post-market: 1.11-0.0200-1.77%19:53 EDT
Volume:432.11K
Turnover:490.39K
Market Cap:14.93M
PE:-1.00
High:1.17
Open:1.17
Low:1.11
Close:1.17
Loading ...

Hoth Therapeutics Inc. to Attend BIO International Convention in Boston

Reuters
·
16 Jun

Hoth Therapeutics Secures Japanese Patent for Innovative HT-KIT Platform Targeting Mast Cell Diseases

Reuters
·
12 Jun

Hoth Therapeutics Secures Japanese Patent for Breakthrough Ht-Kit Platform Targeting Mast Cell Diseases

THOMSON REUTERS
·
12 Jun

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
12 Jun

Hoth Therapeutics Inc. Advances HT-001 with Expanded Access Program Application to Address Severe Skin Toxicities in Cancer Patients

Reuters
·
11 Jun

Hoth Therapeutics Launches Expanded Access Initiative for Ht-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

THOMSON REUTERS
·
11 Jun

Hoth Therapeutics Prepares Presentation on Clinical Programs

TIPRANKS
·
09 Jun

Hoth Therapeutics Secures New Patent Filing for Innovative HT-001 Formulation, Strengthening IP Portfolio in Cancer Care

Reuters
·
05 Jun

Hoth Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Christopher Michael Camarra

Reuters
·
22 May

Hoth Therapeutics Faces Nasdaq Compliance Challenge

TIPRANKS
·
17 May

Hoth Therapeutics Inc. Faces Nasdaq Non-Compliance for Minimum Bid Price Requirement

Reuters
·
17 May

Hoth Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Hoth Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
10 May

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

PR Newswire
·
17 Apr

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
15 Apr

BRIEF-Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial

Reuters
·
15 Apr

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

THOMSON REUTERS
·
15 Apr

Hoth Therapeutics Inc - Patients Experienced a 50% Reduction in Pruritus Severity, With Mean Scores Dropping From 1.6 on Day 1 to 0.8 by Day 21

THOMSON REUTERS
·
15 Apr

Hoth Therapeutics Inc - Ht-001 Was Well Tolerated, With No Treatment-Related Serious Adverse Events Reported

THOMSON REUTERS
·
15 Apr

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

PR Newswire
·
15 Apr